A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy

• Status: Completed
• Trial end date: 2015-02-01
• Target enrollment: 0
• Participant gender: All

Summary

A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft ® as Measured by In-Vivo Confocal Microscopy

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: ORA, Inc.
• Treatments: Alcaftadine; Dextrans

Criteria

Inclusion Criteria:

• Have a positive history of ocular allergies and a positive skin test to protocol defined allergens

• Have a positive CAC reaction at Visit 1

• Have a positive conjunctival inflammation score at Visit 1

Exclusion Criteria:

• May not use disallowed medications in specified washout period

• May not have an ocular or system disease the investigator feels with impact subject safety or trial parameters

• May not have active ocular infection